by United Pompe | Mar 4, 2017 | News
PR NewsWire March 3, 2017 Valerion Therapeutics Demonstrates a New Mechanism for Treating Pompe Disease Concord, MA– March 3, 2017– Valerion Therapeutics announced today that it has developed a fusion protein, VAL-1221, which combines its proprietary...
by United Pompe | Dec 8, 2016 | News
December 8, 2016 Amicus Therapeutics Announces Positive Preliminary Data from Phase 1/2 Study of Novel Treatment Paradigm for Pompe Disease ATB200/AT2221 Safety Data Show No Infusion-Associated Reactions Following 100+ Infusions Clinical Pharmacokinetic (PK) Profile...
by United Pompe | Nov 15, 2016 | News
PRESS RELEASE Sanofi Genzyme Begins Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe Disease Cambridge, Mass. – November 4, 2016 – Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the...
by United Pompe | Jul 18, 2016 | News
Guidance to the Pompe Community
by United Pompe | Jul 18, 2016 | News
Genzyme Program Update November 10th, 2008 Genzyme would like to take this opportunity to provide an update to the Pompe Community. The US Food and Drug Administration (FDA) held a meeting of its Endocrinologic and Metabolic Drugs Advisory Committee on October 21,...
by United Pompe | Jul 18, 2016 | News
Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of